FDA committee supports Aventis' Sculptra for sunken facial features from HIV

An FDA panel gave its blessing to Aventis' Sculptra injection for treating a byproduct of HIV, likely leading to eventual agency approval for the drug, the first for filling in sunken facial features. Panel members said the drug, already approved in Europe as New-Fill, has shown convincing evidence of safety and effectiveness, although some FDA panel members raised concerns about the lack of testing on large numbers of women and minorities and about the drug's possible off-label cosmetic applications.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ